In Brief: Agouron's Viracept
Agouron's Viracept: Legislation introduced Aug. 2 in the House (HR 3977) and Senate (S 2021) to suspend tariffs on compounds needed for the manufacture of the protease inhibitor nelfinavir mesylate. Initial co-sponsors of the bills are California Sens. Feinstein (D) and Boxer (D) and Reps. Bilbray (R), Matsui (D) and Thomas (R). Introducing the bill, Feinstein indicated her interest in attaching S 2021 to tariff legislation pending before the Senate Finance Committee...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth